Figure 1.
Cumulative risk of exposure to IBD-directed therapy among patients with MS-IBD (red) and IBD (green) including time to initiation of (A) any immunosuppressive, (B) tumor necrosis factor inhibitors, (C) vedolizumab, or (D) thiopurines.

Cumulative risk of exposure to IBD-directed therapy among patients with MS-IBD (red) and IBD (green) including time to initiation of (A) any immunosuppressive, (B) tumor necrosis factor inhibitors, (C) vedolizumab, or (D) thiopurines.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close